130 related articles for article (PubMed ID: 38923506)
1. Low Nirmatrelvir and Ritonavir Exposure through Breastmilk: Analyzing Milk Concentrations and Infant Risk.
Dai J; Fuquay T; Huseman S; Patel D; Datta P; Krutsch K
Clin Pharmacol Ther; 2024 Jun; ():. PubMed ID: 38923506
[TBL] [Abstract][Full Text] [Related]
2. Nirmatrelvir combined with ritonavir for preventing and treating COVID-19.
Reis S; Metzendorf MI; Kuehn R; Popp M; Gagyor I; Kranke P; Meybohm P; Skoetz N; Weibel S
Cochrane Database Syst Rev; 2022 Sep; 9(9):CD015395. PubMed ID: 36126225
[TBL] [Abstract][Full Text] [Related]
3. Nirmatrelvir combined with ritonavir for preventing and treating COVID-19.
Reis S; Metzendorf MI; Kuehn R; Popp M; Gagyor I; Kranke P; Meybohm P; Skoetz N; Weibel S
Cochrane Database Syst Rev; 2023 Nov; 11(11):CD015395. PubMed ID: 38032024
[TBL] [Abstract][Full Text] [Related]
4. Alleviating anxiety while breastfeeding: evaluating buspirone transfer into human milk.
Krutsch K; Campbell L; Baker T; Datta P
Arch Womens Ment Health; 2024 Feb; ():. PubMed ID: 38376615
[TBL] [Abstract][Full Text] [Related]
5. Nirmatrelvir-Ritonavir (Paxlovid) for Mild Coronavirus Disease 2019 (COVID-19) in Pregnancy and Lactation.
Lin CY; Cassidy AG; Li L; Prahl MK; Golan Y; Gaw SL
Obstet Gynecol; 2023 May; 141(5):957-960. PubMed ID: 36928334
[TBL] [Abstract][Full Text] [Related]
6. Nirmatrelvir/Ritonavir for hemodialysis patients with COVID-19.
Lu J; Cai H; Hao Y; Lin Z; Liu S; Zhan Y; Ding L; Huang M; Li Z; Xu L; Yan X; Yang L; Zhang H; Zhang W; Zhao L; Zhao J; Wang T; Gu L
Front Pharmacol; 2023; 14():1161897. PubMed ID: 37251313
[No Abstract] [Full Text] [Related]
7. Pre-exposure Prophylaxis Use by Breastfeeding HIV-Uninfected Women: A Prospective Short-Term Study of Antiretroviral Excretion in Breast Milk and Infant Absorption.
Mugwanya KK; Hendrix CW; Mugo NR; Marzinke M; Katabira ET; Ngure K; Semiyaga NB; John-Stewart G; Muwonge TR; Muthuri G; Stergachis A; Celum CL; Baeten JM
PLoS Med; 2016 Sep; 13(9):e1002132. PubMed ID: 27676257
[TBL] [Abstract][Full Text] [Related]
8. Pharmacokinetics of Oral Nirmatrelvir/Ritonavir, a Protease Inhibitor for Treatment of COVID-19, in Subjects With Renal Impairment.
Toussi SS; Neutel JM; Navarro J; Preston RA; Shi H; Kavetska O; LaBadie RR; Binks M; Chan PLS; Demers N; Corrigan B; Damle B
Clin Pharmacol Ther; 2022 Oct; 112(4):892-900. PubMed ID: 35712797
[TBL] [Abstract][Full Text] [Related]
9. Analysis of All-Cause Hospitalization and Death Among Nonhospitalized Patients With Type 2 Diabetes and SARS-CoV-2 Infection Treated With Molnupiravir or Nirmatrelvir-Ritonavir During the Omicron Wave in Hong Kong.
Lui DTW; Chung MSH; Lau EHY; Lau KTK; Au ICH; Lee CH; Woo YC; Wong CKH; Cowling BJ
JAMA Netw Open; 2023 May; 6(5):e2314393. PubMed ID: 37204790
[TBL] [Abstract][Full Text] [Related]
10. Antiviral efficacy of molnupiravir versus ritonavir-boosted nirmatrelvir in patients with early symptomatic COVID-19 (PLATCOV): an open-label, phase 2, randomised, controlled, adaptive trial.
Schilling WHK; Jittamala P; Watson JA; Boyd S; Luvira V; Siripoon T; Ngamprasertchai T; Batty EM; Cruz C; Callery JJ; Singh S; Saroj M; Kruabkontho V; Ngernseng T; Tanglakmankhong N; Tubprasert J; Abdad MY; Madmanee W; Kouhathong J; Suwannasin K; Pagornrat W; Piaraksa N; Hanboonkunupakarn P; Hanboonkunupakarn B; Poovorawan K; Potaporn M; Srisubat A; Loharjun B; Taylor WRJ; Chotivanich V; Chotivanich K; Imwong M; Pukrittayakamee S; Dondorp AM; Day NPJ; Teixeira MM; Piyaphanee W; Phumratanaprapin W; White NJ;
Lancet Infect Dis; 2024 Jan; 24(1):36-45. PubMed ID: 37778363
[TBL] [Abstract][Full Text] [Related]
11. Efficacy and Safety of Nirmatrelvir/Ritonavir in Severe Hospitalized Patients with COVID-19 and in Patients at High Risk for Progression to Critical Illness: A Real-World Study.
Chen X; Zhu Y; Shen L; Zhou D; Feng N; Tong Q
J Intensive Care Med; 2024 Feb; ():8850666241228841. PubMed ID: 38356292
[No Abstract] [Full Text] [Related]
12. The concentration of maternal sacubitril/valsartan transferred into human milk is negligible.
Falconi S; Okimi A; Wesley S; Sethi P; Datta P; Krutsch K
Front Public Health; 2024; 12():1389513. PubMed ID: 38841677
[TBL] [Abstract][Full Text] [Related]
13. Real-world effectiveness of early molnupiravir or nirmatrelvir-ritonavir in hospitalised patients with COVID-19 without supplemental oxygen requirement on admission during Hong Kong's omicron BA.2 wave: a retrospective cohort study.
Wong CKH; Au ICH; Lau KTK; Lau EHY; Cowling BJ; Leung GM
Lancet Infect Dis; 2022 Dec; 22(12):1681-1693. PubMed ID: 36029795
[TBL] [Abstract][Full Text] [Related]
14. Comparison of safety and efficacy between Nirmatrelvir-ritonavir and molnupiravir in the treatment of COVID-19 infection in patients with advanced kidney disease: a retrospective observational study.
Chu WM; Wan EYF; Ting Wong ZC; Tam AR; Kei Wong IC; Yin Chan EW; Ngai Hung IF
EClinicalMedicine; 2024 Jun; 72():102620. PubMed ID: 38737003
[TBL] [Abstract][Full Text] [Related]
15. Nirmatrelvir-ritonavir treatment of COVID-19 in a high-risk patient population: A retrospective observational study.
Kane AM; Keenan EM; Lee K; Hartkopf KJ; Ludwig TA; Trapskin PJ; Vanderloo JP; Schulz LT
J Am Coll Clin Pharm; 2023 Jan; 6(1):29-33. PubMed ID: 36718381
[TBL] [Abstract][Full Text] [Related]
16. Effectiveness of nirmatrelvir-ritonavir against hospital admission or death: a cohort study in a large US healthcare system.
Lewnard JA; McLaughlin JM; Malden D; Hong V; Puzniak L; Ackerson BK; Lewin BJ; Kim JS; Shaw SF; Takhar H; Jodar L; Tartof SY
medRxiv; 2023 Jan; ():. PubMed ID: 36238720
[TBL] [Abstract][Full Text] [Related]
17. Real-world effectiveness of molnupiravir and nirmatrelvir plus ritonavir against mortality, hospitalisation, and in-hospital outcomes among community-dwelling, ambulatory patients with confirmed SARS-CoV-2 infection during the omicron wave in Hong Kong: an observational study.
Wong CKH; Au ICH; Lau KTK; Lau EHY; Cowling BJ; Leung GM
Lancet; 2022 Oct; 400(10359):1213-1222. PubMed ID: 36216007
[TBL] [Abstract][Full Text] [Related]
18. Effectiveness of nirmatrelvir-ritonavir in preventing hospital admissions and deaths in people with COVID-19: a cohort study in a large US health-care system.
Lewnard JA; McLaughlin JM; Malden D; Hong V; Puzniak L; Ackerson BK; Lewin BJ; Kim JS; Shaw SF; Takhar H; Jodar L; Tartof SY
Lancet Infect Dis; 2023 Jul; 23(7):806-815. PubMed ID: 36933565
[TBL] [Abstract][Full Text] [Related]
19. Effect of Hepatic Impairment on the Pharmacokinetics of Nirmatrelvir/Ritonavir, the First Oral Protease Inhibitor for the Treatment of COVID-19.
Singh RSP; LaBadie RR; Toussi SS; Shi H; Berg JK; Neutel JM; Aggarwal S
J Clin Pharmacol; 2024 Feb; 64(2):145-154. PubMed ID: 37751891
[TBL] [Abstract][Full Text] [Related]
20.
; ; . PubMed ID:
[No Abstract] [Full Text] [Related]
[Next] [New Search]
